AAN 2025: CAR T-cell therapy for MS shows safety, efficacy in trials
KYV-101 tested in PPMS, SPMS patients in 2 Phase 1 studies by Andrea Lobo, PhD | April 15, 2025 Kyverna Therapeutics’ CAR T-cell…
Categories
Latest Blog Posts
- AI tool effectively measures MS disease activity from 1 MRI scan
- Understanding the Causes and Symptoms of Leg Cramps
- AAN 2025: CAR T-cell therapy for MS shows safety, efficacy in trials
- Managing the Cost of Long-Term Care
- A Short Guide to Disability Benefits for Veterans with MS
- Share Your Story: Military and Veterans Living with MS
- What Migraine Treatment is Right for You?
- Is Blue Light Messing With Your Sleep?
- Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
- Demyelination and Demyelinating Disease
- Study Finds Smoking and Obesity Interact to Speed Progression of MS
- Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
- The Ultimate Travel Checklist for the Person with MS
- URGENT Message: MS Research Program (MSRP) Unfunded in Fiscal Year 2025 by Congress
- What to Know About Multiple Sclerosis Progression in Chart Form
- How a Portable Electric Mobility Scooter Can Transform Your Independence
- Multiple Sclerosis Activism and Healthcare
- 7 Things ER Doctors Say You Should Always Do After A Fall
- How to Get Through a Spinal Tap to Confirm an MS Diagnosis
- Fatigue in MS – a disabling symptom
